New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice

New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice
CME, CPE
James O. Armitage, MD; and Matthew Lunning, DO, FACP
 
Release Date: October 28, 2022
Expiration Date: October 28, 2023

In this activity, Dr. Lunning will address key data from recent publications and conferences on current and emerging approaches for the treatment of relapsed/refractory DLBCL. To conclude, Dr. Armitage and Dr. Lunning will discuss current and potential practice implications.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb and
Genentech, a member of the Roche Group.
Begin, Earn CreditView Only, No Credit
 

© 2022 MediCom Worldwide, Inc. All rights reserved